![Cancers | Free Full-Text | Predictive Nomogram for Early Recurrence after Pancreatectomy in Resectable Pancreatic Cancer: Risk Classification Using Preoperative Clinicopathologic Factors Cancers | Free Full-Text | Predictive Nomogram for Early Recurrence after Pancreatectomy in Resectable Pancreatic Cancer: Risk Classification Using Preoperative Clinicopathologic Factors](https://www.mdpi.com/cancers/cancers-12-00137/article_deploy/html/images/cancers-12-00137-g001.png)
Cancers | Free Full-Text | Predictive Nomogram for Early Recurrence after Pancreatectomy in Resectable Pancreatic Cancer: Risk Classification Using Preoperative Clinicopathologic Factors
![PDF) Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model PDF) Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model](https://i1.rgstatic.net/publication/353645434_Improved_risk_estimation_of_locoregional_recurrence_secondary_contralateral_tumors_and_distant_metastases_in_early_breast_cancer_the_INFLUENCE_20_model/links/6108d0631e95fe241aa5c6fa/largepreview.png)
PDF) Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model
![PDF) Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data PDF) Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data](https://www.researchgate.net/publication/333011171/figure/fig3/AS:890438512807937@1589308493475/Nomogram-to-predict-for-a-low-risk-Oncotype-DX-ODX-score-TAILORx-clinical-trial_Q320.jpg)
PDF) Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data
![A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients | Scientific Reports A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-61535-9/MediaObjects/41598_2020_61535_Fig1_HTML.png)
A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients | Scientific Reports
![Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data - ScienceDirect Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0960977619305004-gr3.jpg)
Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data - ScienceDirect
![Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor | Scientific Reports Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-53482-x/MediaObjects/41598_2019_53482_Fig1_HTML.png)
Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor | Scientific Reports
![Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer | Nature Reviews Clinical Oncology Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer | Nature Reviews Clinical Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41571-018-0145-5/MediaObjects/41571_2018_145_Fig1_HTML.png)
Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer | Nature Reviews Clinical Oncology
![Frontiers | A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer Frontiers | A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer](https://www.frontiersin.org/files/Articles/1119105/fendo-14-1119105-HTML-r1/image_m/fendo-14-1119105-g001.jpg)
Frontiers | A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer
![Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer - ScienceDirect Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1879406819303534-gr3.jpg)
Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer - ScienceDirect
![Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer - ScienceDirect Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1879406819303534-gr1.jpg)
Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer - ScienceDirect
![Cancers | Free Full-Text | Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy Cancers | Free Full-Text | Multimodal Prediction of Five-Year Breast Cancer Recurrence in Women Who Receive Neoadjuvant Chemotherapy](https://pub.mdpi-res.com/cancers/cancers-14-03848/article_deploy/html/images/cancers-14-03848-g001.png?1660053841)